Jon Giles is a Rheumatology/Immunology physician affiliated with Cedars-Sinai Medical Center. OpenAlex indexes 230 publications with 11,633 citations (h-index 55); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
8723 Alden Dr
Los Angeles, CA 900483692
Telephone
310-423-6257Provider last certified this registry record 9 Feb 2024.
Clinical trials
- Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19)
Sponsor: Columbia University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
13 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- F. Hoffmann-La Roche AGProgram year20253 payments
- Janssen Scientific Affairs, LLCProgram year202545 payments
- PFIZER INC.Program year202516 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
35.5%Folate Analog Metabolic Inhibitor22.2%Methotrexate100%Part D≥19 patientsNonsteroidal Anti-inflammatory Drug7.4%Celecoxib100%Part D<11 patients+ 1 more class in this area
Antiparasitic
19.7%Antimalarial19.7%Hydroxychloroquine Sulfate100%Part D≥14 patientsMusculoskeletal
17.7%Muscle Relaxant10.3%Cyclobenzaprine Hcl100%Part D<11 patientsXanthine oxidase inhibitor7.4%Allopurinol100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2025–2025 per NIH RePORTER. The latest:
- Neuroimaging Measures of Psychosocial Stress as Predictors of Articular and Arterial Inflammation and Treatment Response in Rheumatoid Arthritis
Cedars-Sinai Medical Center
FY2025$447,731R01AR077187
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Shared inflammatory pathways of rheumatoid arthritis and atherosclerotic cardiovascular disease
Nature Reviews Rheumatology
2023 - Reducing cardiovascular risk with immunomodulators: a randomised active comparator trial among patients with rheumatoid arthritis
Annals of the Rheumatic Diseases
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Beth Karlan, MD
Cedars-Sinai Medical Center
Raj Makkar, MD
Cedars-Sinai Medical Center
Paul Noble, MD
Cedars-Sinai Medical Center
Stephen Freedland, MD
Cedars-Sinai Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”